Modular Platforms to Advance Gene Therapy Development

Andelyn’s platform solutions are designed to support the evolving needs of cell and gene therapies across modalities, stages, and complexities. From early research through clinical and commercial readiness, these platforms bring together scientific expertise, flexible process development, and scalable manufacturing to help teams move forward with clarity and confidence.

AAV Curator® Platform

Built on data and configurability, the AAV Curator® platform tailors the manufacturing process to your program’s specific needs to optimize yields and performance. It accounts for key variables across upstream, downstream, and fill-and-finish, including materials, testing, and release parameters.

Explore the AAV Curator

LVV Curator® Platform

Our LVV Curator® Platform uses the same proven modular approach as our AAV platform, standardized where it matters, flexible where it counts, supporting efficient development and manufacturing to meet each client’s needs.

Explore the LVV Curator

Optimization-By-Design™

Industrializing Gene Therapy Processes with a Reductionist, Holistic and Systematic Optimization Methodology Approach

configurable icon
Configurable
Modular platform with assessment and strategy adapted to each program drives faster optimization viral vector manufacturing and Adeno-associated virus (AAV) gene therapy.
key activities icon
Optimization Toolkit
QbD guidelines and DoEs with a lean, step-wise focus on process development maximize program efficiency and ensure high-quality outcomes for cell culture and AAV vector production and purification.
data driven icon
Data Driven
Historical data is leveraged to achieve high-quality gene therapy products with predictable performance in AAV CDMO services.

Consistency in productivity and quality are evaluated at each stage of development and measured with enabling technologies.

full program partnering chart

Benefits of Our Platform Approach

piggy bank icon
Savings

Reduced Spending on Optimization

High Productivity and % Full Capsids driving production costs down

No MCB Generation Costs

No Tech Transfer Costs

No PreClinical/clinical Licensing Fees

stopwatch icon
Expedited Timelines

Reduced time spent on opTimization

Off the Shelf (OTS) plasmids readily avaIlable

No MCB generatIon time

Supply Chain Already Established

NO TECH TRANSFER/DOCUMENTATION TIME

smooth cmc icon
Smooth CMC

DMFs filed for Andelyn’s platform

Same equipment in non-GMP & GMP

Same quality systems

Integrated teams in Preclinical & Clinical

Hear from Our Partners

Success Stories
Learn More About Us
“Working with Andelyn was a great choice given their history with the product, their extensive multi-product experience with the manufacturing technology used for the product, and our desire to quickly bring UX111 to MPS IIIA patients.”
Dennis Huang
Chief Technical Operations Officer and EVP, Gene Therapy Research and Development
Ultragenyx
“Purespring is excited to build on our longstanding working relationship with Andelyn to accelerate the preclinical and clinical manufacture of our innovative AAV-based gene therapies.”
Julian Hanak
CEO
Purespring Therapeutics

Does your program use another vector rather than AAV?

Check out our Tech Transfer capabilities.

Learn More
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.